-
1Academic Journal
Authors: G. А. Chizh, I. V. Rykov, D. S. Orlova, S. О. Kuzin, А. В. Elmurzaev, А. В. Shishkin, V. V. Bogomolov, Г. А. Чиж, И. В. Рыков, Д. С. Орлова, С. О. Кузин, А. Б. Эльмурзаев, А. Б. Шишкин, В. В. Богомолов
Source: Malignant tumours; Том 14, № 1 (2024); 74-82 ; Злокачественные опухоли; Том 14, № 1 (2024); 74-82 ; 2587-6813 ; 2224-5057
Subject Terms: лечение нейропатии, chemotherapy-induced peripheral neuropathy, taxanes, derivatives of platinum, neuropathy treatment, нейропатия, химиоиндуцированная периферическая нейропатия, таксаны, препараты платины
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1288/918; William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031; Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020; NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category =1&id =1462; NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf; NCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf; Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020; Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772–781. https://doi.org/10.1002/ana.24951; Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010; Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708–16. https://doi.org/10.1634/theoncologist.2010-0248; Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312; Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470–1. https://doi.org/10.1212/01.wnl.0000032505.45389.94; Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337–40. https://doi.org/10.1212/01.wnl.0000043691.53710.53; Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316–20. https://doi.org/10.1097/00043426-200304000-00010; Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461–7469. https://doi.org/10.1007/s00520-021-06321-7; McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769–5776. https://doi.org/10.1158/1078-0432.CCR-13-0774; Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707–714. https://doi.org/10.1007/s10549-020-05584-8; Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014–22. https://doi.org/10.1200/JCO.2015.66.2346; Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5; EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2; Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174; Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42. https://doi.org/10.1200/JCO.2005.04.0543; de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. https://doi.org/10.1200/JCO.2000.18.16.2938; Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419–37. https://doi.org/10.3322/caac.21204. PMID: 2459086; Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399; Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003; Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667–4678. https://doi.org/10.21873/anticanres.15971; Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727–1737. https://doi.org/10.1093/brain/awab113; Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126–1137. https://doi.org/10.1097/j.pain.0000000000000893; Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. https://doi.org/10.1016/j.expneurol.2011.08.016; Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687; Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813; Farshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787–793. https://doi.org/10.1007/s00280-018-3664-y; Matsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182; Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627–33. https://doi.org/10.1200/JCO.2012.44.8738; Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043; Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359–61. https://doi.org/10.1200/JCO.2002.99.502; Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223–31. https://doi.org/10.1007/s00520-013-2075-1; Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739–4754. https://doi.org/10.26355/eurrev_201807_15534.2018; Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146–51. https://doi.org/10.3816/CCC.2006.n.032; https://www.malignanttumors.org/jour/article/view/1288
-
2Academic Journal
Authors: Политова, Е., Заваденко, Н., Румянцев, А.
Subject Terms: ХИМИОТЕРАПИЯ, НЕРВНО-МЫШЕЧНЫЕ ОСЛОЖНЕНИЯ, МИОПАТИЯ, ХИМИОИНДУЦИРОВАННАЯ ПЕРИФЕРИЧЕСКАЯ НЕЙРОПАТИЯ
File Description: text/html
-
3Academic Journal
Source: Онкогематология.
Subject Terms: ХИМИОТЕРАПИЯ, НЕРВНО-МЫШЕЧНЫЕ ОСЛОЖНЕНИЯ, МИОПАТИЯ, ХИМИОИНДУЦИРОВАННАЯ ПЕРИФЕРИЧЕСКАЯ НЕЙРОПАТИЯ, 3. Good health
File Description: text/html
